HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on CalciMedica (NASDAQ:CALC) and maintained a $20 price target. This reaffirms the firm's positive outlook on the company.
February 13, 2024 | 5:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on CalciMedica and maintains a $20 price target, indicating a strong positive outlook on the company.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst suggests a strong conviction in the company's future performance. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100